Although there are no PIK3CA-targeted drugs specifically approved for bladder cancer, different PI3K inhibitors have been approved by FDA, but not in monotherapy for solid tumours, including bladder cancer [115]. This evidence concerns the gene PIK3CA and urinary bladder cancer.